ClinicalTrials.gg
CompletedNCT05001945Target-HTNUpdated Jan 5, 2024Results posted

Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension

A Phase 2 interventional study of MLS-101 (Part I) and Placebo (Part I) in Hypertension, Renal, sponsored by Mineralys Therapeutics Inc.. Completed at 44 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by Mineralys Therapeutics Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A randomized, double-blind, placebo-controlled, dose-ranging, Phase II study to evaluate the safety, efficacy, and tolerability of MLS-101 in Subjects With Uncontrolled Hypertension

02

Conditions studied

  • Hypertension, Renal

Keywords

  • Blood pressure
  • Uncontrolled hypertension
  • Phase II
03

In context

Lead sponsor

Mineralys Therapeutics Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and nonpregnant, nonlactating female subjects ≥ 18 years of age.
  2. Written Health Insurance Portability and Accountability Act authorization, and local patient privacy required documentation for this study have been obtained
  3. Automated office blood pressure (AOBP) with SBP ≥ 130 mm Hg
  4. Background antihypertensive treatment of ≥ 2 drugs
  5. Serum cortisol ≥ 18 mcg/dL

Exclusion criteria

Exclusion Criteria:

  1. Concomitant use of epithelial sodium channel inhibitors or mineralocorticoid receptor antagonists
  1. Subjects with hypokalemia
  1. Subjects with hyperkalemia
  1. Subjects with serum cortisol \< 3 mcg/dL
  1. Subjects with serum sodium \< 135 mEq/L
  1. Subjects with estimated \< 60 mL/min/1.73m2
  1. Subjects with type 1 or uncontrolled ( ≥ 9%) type 2 diabetes mellitus
  1. Subjects with > 40 kg/m2
  1. Subjects with unstable angina
  1. Subjects with SBP ≥ 175 mm Hg or DBP ≥ 100 mm Hg for Part 1 and SBP ≥ 160 mm Hg or DBP ≥ 100 mm Hg for Part 2 at Pre-Screening, Screening/Start of Placebo Run-in, or Randomization
  1. Subjects with a decrease in SBP ≥ 20 mm Hg or DBP ≥ 10 mm Hg from sitting to standing position at screening
  1. Subjects who, in the opinion of the investigator, have suspected nonadherence to antihypertensive treatment
  1. Subjects who, in the opinion of the investigator, have any major medical illness or symptoms
  1. Subjects who, in the opinion of the investigator, have any acute or chronic medical or psychiatric condition
  1. Subjects undergoing treatment with any of the following medications:
  1. Topical corticoids
  2. Sympathomimetic decongestants
  3. Theophylline
  4. Phosphodiesterase type 5 inhibitors
  5. NSAIDs
  6. Intramuscular
  7. Estrogen
  8. Cytochromes
  9. Strong and CYP3A4 inducers

    1. Subjects with known to MLS-101 or any of the
    1. Subjects who are night-shift workers
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (actual)

Study arms

  • Placebo comparator
    Placebo (Part I)

    Placebo tablet(s) by mouth once or twice daily.

    Other: Placebo (Part I)

  • Experimental
    Dose 1 (Part I)

    MLS-101 tablet(s) by mouth once or twice daily.

    Drug: MLS-101 (Part I)

  • Experimental
    Dose 2 (Part I)

    MLS-101 tablet(s) by mouth once or twice daily.

    Drug: MLS-101 (Part I)

  • Experimental
    Dose 3 (Part I)

    MLS-101 tablet(s) by mouth once or twice daily.

    Drug: MLS-101 (Part I)

  • Placebo comparator
    Placebo (Part II)

    Placebo tablet(s) by mouth once daily.

    Other: Placebo (Part II)

  • Experimental
    Dose (Part II)

    MLS-101 tablet(s) by mouth once daily.

    Drug: MLS-101 (Part II)

Interventions

  • MLS-101 tablet(s) by mouth once or twice daily.

  • OtherPlacebo (Part I)

    Placebo tablet(s) by mouth once or twice daily.

  • OtherPlacebo (Part II)

    Placebo tablet(s) by mouth once daily.

  • MLS-101 tablet(s) by mouth once daily.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Office-measured Systolic Blood Pressure (SBP) at Study Week 8 Compared to Placebo

    The primary outcome was defined as the change in office-measured (mean of last 2 of 5 unattended measurements using an automated oscillometric sphygmomanometer device after approximately 5 minutes of rest in the seated position) SBP from baseline to the end of Study Week 8. The primary efficacy analysis was performed using a mixed model repeated measures (MMRM) approach with defined fixed effects per the statistical analysis plan. A least-square estimate of the mean difference between each dose group and the placebo group is provided for Week 8.

    Time frame: 8 Weeks

Secondary outcomes

  1. Change in 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean Systolic Blood Pressure (SBP) and Mean Diastolic Blood Pressure (DBP) From Baseline to End of Treatment (EoT)

    The ABPM SBP was measured at baseline and EoT. Change in ABPM-derived mean SBP and DBP from baseline to EoT was analyzed using an ANCOVA with a term for treatment group and a baseline mean 24-hour value as a covariate.

    Time frame: 8 Weeks

  2. Week 8 Change From Baseline in Office-measured Diastolic Blood Pressure (DBP)

    Change in office-measured (average of last 2 of 5 unattended measurements using an automated oscillometric sphygmomanometer device after approximately 5 minutes of rest in the seated position) DBP from baseline to the end of study at week 8.

    Time frame: 8 weeks

  3. Number of Participants With Blood Pressure ≤ 130/80 mmHg at Week 8

    Each participant was assessed as a success if the Week 8 value for SBP was ≤130 mmHg and DBP ≤80 mmHg; subjects not meeting both these thresholds were assessed as a failure. Subjects missing an assessment at Week 8 or who received rescue medications were also considered failures.

    Time frame: 8 Weeks

07

Results

Posted Jan 5, 2024
Limitations and caveats
Following the completion of the planned interim analysis in January 2022, the two lowest doses in Part 1 (i.e., 12.5 mg QD and 12.5 mg BID) were dropped from the study and no further subjects were enrolled in these treatment arms. Accordingly, overall subject numbers in these arms is less than originally planned.

Participant flow

Participant flow — Overall Study
MilestonePlacebo - Part 1Lorundrostat 12.5 mg BID - Part 1Lorundrostat 25 mg BID - Part 1Lorundrostat 12.5 mg QD - Part 1Lorundrostat 50 mg QD - Part 1Lorundrostat 100 mg QD - Part 1Placebo - Part 2Lorundrostat 100 mg QD - Part 2
Started302230232830631
Completed291828182627630
Not completed14252301
Withdrew: Adverse event00010000
Withdrew: Lost to follow-up01120100
Withdrew: Protocol violation10110100
Withdrew: Withdrawal by subject00011101
Withdrew: Not specified by investigator03001000

Outcome measures

PrimaryChange From Baseline in Office-measured Systolic Blood Pressure (SBP) at Study Week 8 Compared to Placebo

The primary outcome was defined as the change in office-measured (mean of last 2 of 5 unattended measurements using an automated oscillometric sphygmomanometer device after approximately 5 minutes of rest in the seated position) SBP from baseline to the end of Study Week 8. The primary efficacy analysis was performed using a mixed model repeated measures (MMRM) approach with defined fixed effects per the statistical analysis plan. A least-square estimate of the mean difference between each dose group and the placebo group is provided for Week 8.

Time frame:
8 Weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in Office-measured Systolic Blood Pressure (SBP) at Study Week 8 Compared to Placebo
mmHgPlacebo - Part 1Lorundrostat 12.5 mg BID - Part 1Lorundrostat 25 mg BID - Part 1Lorundrostat 12.5 mg QD - Part 1Lorundrostat 50 mg QD - Part 1Lorundrostat 100 mg QD - Part 1Placebo - Part 2Lorundrostat 100 mg QD - Part 2
Change From Baseline in Office-measured Systolic Blood Pressure (SBP) at Study Week 8 Compared to Placebo-4.10 ± 2.62-11.3 ± 3.15-11.07 ± 2.65-5.63 ± 3.16-13.69 ± 2.67-11.92 ± 2.77—-11.43 ± 2.41
SecondaryChange in 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean Systolic Blood Pressure (SBP) and Mean Diastolic Blood Pressure (DBP) From Baseline to End of Treatment (EoT)

The ABPM SBP was measured at baseline and EoT. Change in ABPM-derived mean SBP and DBP from baseline to EoT was analyzed using an ANCOVA with a term for treatment group and a baseline mean 24-hour value as a covariate.

Time frame:
8 Weeks
Reported as:
Least squares mean · mmHg
Change in 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean Systolic Blood Pressure (SBP) and Mean Diastolic Blood Pressure (DBP) From Baseline to End of Treatment (EoT)
mmHgPlacebo - Part 1Lorundrostat 12.5 mg BID - Part 1Lorundrostat 25 mg BID - Part 1Lorundrostat 12.5 mg QD - Part 1Lorundrostat 50 mg QD - Part 1Lorundrostat 100 mg QD - Part 1Placebo - Part 2Lorundrostat 100 mg QD - Part 2
Mean SBP-1.01 ± 2.38-5.78 ± 3.03-9.05 ± 2.38-2.51 ± 3.15-4.86 ± 2.34-6.34 ± 2.5—-1.02 ± 2.64
Mean DBP-0.90 ± 1.46-5.14 ± 1.85-6.03 ± 1.45-2.34 ± 1.91-3.64 ± 1.40-6.14 ± 1.51—-0.07 ± 1.69
SecondaryWeek 8 Change From Baseline in Office-measured Diastolic Blood Pressure (DBP)

Change in office-measured (average of last 2 of 5 unattended measurements using an automated oscillometric sphygmomanometer device after approximately 5 minutes of rest in the seated position) DBP from baseline to the end of study at week 8.

Time frame:
8 weeks
Reported as:
Least squares mean · mmHg
Week 8 Change From Baseline in Office-measured Diastolic Blood Pressure (DBP)
mmHgPlacebo - Part 1Lorundrostat 12.5 mg BID - Part 1Lorundrostat 25 mg BID - Part 1Lorundrostat 12.5 mg QD - Part 1Lorundrostat 50 mg QD - Part 1Lorundrostat 100 mg QD - Part 1Placebo - Part 2Lorundrostat 100 mg QD - Part 2
Week 8 Change From Baseline in Office-measured Diastolic Blood Pressure (DBP)-1.63 ± 1.66-5.47 ± 2.02-4.12 ± 1.68-3.76 ± 2.02-7.09 ± 1.70-5.75 ± 1.77—-5.55 ± 1.42
SecondaryNumber of Participants With Blood Pressure ≤ 130/80 mmHg at Week 8

Each participant was assessed as a success if the Week 8 value for SBP was ≤130 mmHg and DBP ≤80 mmHg; subjects not meeting both these thresholds were assessed as a failure. Subjects missing an assessment at Week 8 or who received rescue medications were also considered failures.

Time frame:
8 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Blood Pressure ≤ 130/80 mmHg at Week 8
ParticipantsPlacebo - Part 1Lorundrostat 12.5 mg BID - Part 1Lorundrostat 25 mg BID - Part 1Lorundrostat 12.5 mg QD - Part 1Lorundrostat 50 mg QD - Part 1Lorundrostat 100 mg QD - Part 1Placebo - Part 2Lorundrostat 100 mg QD - Part 2
Number of Participants With Blood Pressure ≤ 130/80 mmHg at Week 877136129317

Adverse events

Collected over 12 weeks; two weeks for Run-in Phase treatment-emergent adverse events (TEAEs) reporting and ten weeks for on-treatment (i.e., post-randomization) TEAE reporting.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo - Part 10/30 (0%)0/30 (0%)7/30 (23.3%)
Lorundrostat 12.5 mg BID - Part 10/22 (0%)0/22 (0%)13/22 (59.1%)
Lorundrostat 25 mg BID - Part 10/30 (0%)0/30 (0%)18/30 (60%)
Lorundrostat 12.5 mg QD - Part 10/23 (0%)2/23 (8.7%)16/23 (69.6%)
Lorundrostat 50 mg QD - Part 10/28 (0%)0/28 (0%)10/28 (35.7%)
Lorundrostat 100 mg QD - Part 10/30 (0%)0/30 (0%)16/30 (53.3%)
Placebo - Part 20/6 (0%)0/6 (0%)1/6 (16.7%)
Lorundrostat 100 mg QD - Part 20/31 (0%)1/31 (3.2%)19/31 (61.3%)
Run-in0/305 (0%)0/305 (0%)8/305 (2.6%)
Most frequent serious events
Most frequent serious events
EventPlacebo - Part 1Lorundrostat 12.5 mg BID - Part 1Lorundrostat 25 mg BID - Part 1Lorundrostat 12.5 mg QD - Part 1Lorundrostat 50 mg QD - Part 1Lorundrostat 100 mg QD - Part 1Placebo - Part 2Lorundrostat 100 mg QD - Part 2Run-in
Coronary artery diseaseCardiac disorders0/300/220/301/230/280/300/60/310/305
Metastases to peritoneumNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/300/220/301/230/280/300/60/310/305
HyponatremiaMetabolism and nutrition disorders0/300/220/300/230/280/300/61/310/305
Most frequent other events
Showing 10 of 34
Most frequent other events
EventPlacebo - Part 1Lorundrostat 12.5 mg BID - Part 1Lorundrostat 25 mg BID - Part 1Lorundrostat 12.5 mg QD - Part 1Lorundrostat 50 mg QD - Part 1Lorundrostat 100 mg QD - Part 1Placebo - Part 2Lorundrostat 100 mg QD - Part 2Run-in
HyperkalemiaMetabolism and nutrition disorders1/305/229/306/233/288/300/68/313/305
Blood sodium decreasedInvestigations0/300/220/300/230/280/301/60/310/305
Glomerular filtration rate decreasedInvestigations1/303/220/301/230/285/300/61/310/305
Diabetes mellitusMetabolism and nutrition disorders0/301/220/300/230/280/301/60/310/305
Urinary Tract InfectionInfections and infestations0/300/223/301/232/281/300/62/310/305
Blood creatinine increasedInvestigations0/300/220/300/230/283/300/61/310/305
Muscle spasmsMusculoskeletal and connective tissue disorders0/300/220/300/230/281/300/63/310/305
Cortisol decreasedInvestigations1/302/221/300/230/280/300/60/310/305
HypertensionVascular disorders0/300/221/302/232/280/300/60/311/305
Orthostatic hypotensionVascular disorders0/301/220/302/230/280/300/60/310/305

Baseline characteristics

The Baseline Analysis Population consisted of all randomized subjects. This analysis set was used for summaries of subject study disposition, with subjects analyzed according to the randomized study treatment group they were assigned to.

Age, Continuous
Age, Continuous(years)Placebo - Part 1Lorundrostat 12.5 mg BID - Part 1Lorundrostat 25 mg BID - Part 1Lorundrostat 12.5 mg QD - Part 1Lorundrostat 50 mg QD - Part 1Lorundrostat 100 mg QD - Part 1Placebo - Part 2Lorundrostat 100 mg QD - Part 2Total
Mean62.6 ± 10.768.1 ± 10.164.8 ± 9.765.2 ± 11.364.7 ± 9.568.7 ± 8.962.7 ± 12.366.6 ± 10.665.7 ± 10.2
Age, Customized
Age, Customized(Participants)Placebo - Part 1Lorundrostat 12.5 mg BID - Part 1Lorundrostat 25 mg BID - Part 1Lorundrostat 12.5 mg QD - Part 1Lorundrostat 50 mg QD - Part 1Lorundrostat 100 mg QD - Part 1Placebo - Part 2Lorundrostat 100 mg QD - Part 2Total
<6517614101594883
65-79121315101317222104
>=801313040113
Sex: Female, Male
Sex: Female, Male(Participants)Placebo - Part 1Lorundrostat 12.5 mg BID - Part 1Lorundrostat 25 mg BID - Part 1Lorundrostat 12.5 mg QD - Part 1Lorundrostat 50 mg QD - Part 1Lorundrostat 100 mg QD - Part 1Placebo - Part 2Lorundrostat 100 mg QD - Part 2Total
Female171419121518421120
Male1381111131221080
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo - Part 1Lorundrostat 12.5 mg BID - Part 1Lorundrostat 25 mg BID - Part 1Lorundrostat 12.5 mg QD - Part 1Lorundrostat 50 mg QD - Part 1Lorundrostat 100 mg QD - Part 1Placebo - Part 2Lorundrostat 100 mg QD - Part 2Total
Hispanic or Latino1271710141621795
Not Hispanic or Latino181513121413412101
Unknown or Not Reported000101024
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo - Part 1Lorundrostat 12.5 mg BID - Part 1Lorundrostat 25 mg BID - Part 1Lorundrostat 12.5 mg QD - Part 1Lorundrostat 50 mg QD - Part 1Lorundrostat 100 mg QD - Part 1Placebo - Part 2Lorundrostat 100 mg QD - Part 2Total
American Indian or Alaska Native000000000
Asian100101003
Native Hawaiian or Other Pacific Islander000000000
Black or African American1677118152672
White131523111914425124
More than one race000000000
Unknown or Not Reported000010001
Region of Enrollment
Region of Enrollment(participants)Placebo - Part 1Lorundrostat 12.5 mg BID - Part 1Lorundrostat 25 mg BID - Part 1Lorundrostat 12.5 mg QD - Part 1Lorundrostat 50 mg QD - Part 1Lorundrostat 100 mg QD - Part 1Placebo - Part 2Lorundrostat 100 mg QD - Part 2Total
United States302230232830631200
Body Mass Index
Body Mass Index(kg/m^2)Placebo - Part 1Lorundrostat 12.5 mg BID - Part 1Lorundrostat 25 mg BID - Part 1Lorundrostat 12.5 mg QD - Part 1Lorundrostat 50 mg QD - Part 1Lorundrostat 100 mg QD - Part 1Placebo - Part 2Lorundrostat 100 mg QD - Part 2Total
Mean31.9 ± 4.932 ± 5.230.6 ± 5.530.6 ± 4.932.0 ± 5.030.4 ± 5.532.0 ± 3.930.5 ± 4.431.1 ± 5.0
Seated Automated Office-measured Systolic Blood Pressure
Seated Automated Office-measured Systolic Blood Pressure(mmHg)Placebo - Part 1Lorundrostat 12.5 mg BID - Part 1Lorundrostat 25 mg BID - Part 1Lorundrostat 12.5 mg QD - Part 1Lorundrostat 50 mg QD - Part 1Lorundrostat 100 mg QD - Part 1Placebo - Part 2Lorundrostat 100 mg QD - Part 2Total
Mean142.9 ± 10.7142.6 ± 13.3142.8 ± 13.1142.9 ± 13.7140.0 ± 12.1142.2 ± 13.4135.3 ± 5.5139.8 ± 9.1141.6 ± 12.0

1 further baseline measures are reported on the registry.

08

Study locations

44 sites
  • Site 103
    Lincoln, California 95648, United States
  • Site 129
    Torrance, California 90502, United States
  • Site 135
    Tustin, California 92780, United States
  • Site 131
    Clearwater, Florida 33765, United States
  • Site 105
    Coral Gables, Florida 33134, United States
  • Site 108
    Greenacres City, Florida 33467, United States
  • Site 134
    Jupiter, Florida 33458, United States
  • Site 146
    Miami, Florida 33126, United States
  • Site 137
    Miami, Florida 33135, United States
  • Site 139
    Miami, Florida 33135, United States
  • Site 143
    Miami, Florida 33144, United States
  • Site 122
    Pembroke Pines, Florida 33026, United States
  • Site 102
    Tampa, Florida 91303, United States
  • Site 118
    Albany, Georgia 31707, United States
  • Site 109
    Fayetteville, Georgia 30214, United States
  • Site 125
    Lawrenceville, Georgia 30044, United States
  • Site 136
    Arlington Heights, Illinois 60005, United States
  • Site 138
    Bossier City, Louisiana 71111, United States
  • Site 154
    Hammond, Louisiana 70403, United States
  • Site 148
    Shreveport, Louisiana 71105, United States
  • Site 114
    Slidell, Louisiana 70458, United States
  • Site 116
    Jefferson City, Missouri 65109, United States
  • Site 121
    Saint Louis, Missouri 63141, United States
  • Site 123
    Las Vegas, Nevada 89121, United States
  • Site 141
    Jamaica, New York 11432, United States
  • Site 133
    Asheboro, North Carolina 27203, United States
  • Site 113
    Charlotte, North Carolina 28210, United States
  • Site 130
    Fayetteville, North Carolina 28304, United States
  • Site 140
    Greensboro, North Carolina 27408, United States
  • Site 104
    Morgantown, North Carolina 28655, United States
  • Site 150
    Raleigh, North Carolina 27612, United States
  • Site 153
    Cleveland, Ohio 44195, United States
  • Site 115
    Rapid City, South Dakota 57702, United States
  • Site 107
    Chattanooga, Tennessee 37421, United States
  • Site 120
    Kingsport, Tennessee 37660, United States
  • Site 152
    Nashville, Tennessee 37232, United States
  • Site 151
    Arlington, Texas 76012, United States
  • Site 145
    Cypress, Texas 77429, United States
  • Site 132
    Dallas, Texas 75224, United States
  • Site 124
    McKinney, Texas 75071, United States
  • Site 147
    Mesquite, Texas 75149, United States
  • Site 126
    Pearland, Texas 77584, United States
  • Site 128
    Richland Hills, Texas 76180, United States
  • Site 112
    Forest, Virginia 24551, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Sep 2022, 14 months.

Results were first posted in Jan 2024, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2021
First posted
Aug 12, 2021
StartActual
Jul 1, 2021
Primary completionActual
Sep 7, 2022
CompletionActual
Oct 7, 2022
Results first posted
Jan 5, 2024
Last update
Jan 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05001945
Lead sponsor
Mineralys Therapeutics Inc.
Responsible party
Sponsor
First posted
Aug 12, 2021
Start date
Jul 1, 2021
Primary completion
Sep 7, 2022
Completion
Oct 7, 2022
Results posted
Jan 5, 2024
Last update
Jan 5, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lorundrostat hydrobromide

Start the discussion